tiprankstipranks
Advertisement
Advertisement

Monopar Therapeutics reports Q2 EPS (35c), consensus (48c)

Cash, cash equivalents and investments as of June 30, 2025, were $53.3 million. Monopar expects that its current funds will be sufficient to continue operations at least through December 31, 2026.

Claim 30% Off TipRanks

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1